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Abstract
Background: Guidelines on urinary incontinence recommend that absorbent products are only used as a coping
strategy pending definitive treatment, as an adjunct to ongoing therapy, or for long-term management after all
treatment options have been explored. However, these criteria are rarely met and a significant share of long-term
product users could still benefit from therapeutic interventions recommended in guidelines for urinary incontinence.
Better implementation of these guidelines can potentially result in both health benefits for women and long-term
cost savings for society. The aim of the COCON study is to evaluate the (cost-)effectiveness of a nurse-led intervention
to optimise implementation of guideline-concordant continence care in comparison with usual care for urinary
incontinent women aged 55 years and over who use absorbent products.
Methods: This randomised clinical trial compares usual care with a nurse-led intervention to optimise implementation
of guideline-concordant continence care. Women (anticipated N = 160) are recruited in 12 community pharmacies in
three Dutch regions, and are eligible for trial entry when they are 55 years and over, community-dwelling and long-
term users of absorbent products (≥4 months) reimbursed by health insurance. Measurements are administered at
baseline, 3, 6 and 12 months. Primary outcome is severity of urinary incontinence (ICIQ-UI SF); other outcomes include
health related quality of life (EQ-5D-5 L), use of absorbent products (in accordance with the recommended criteria in
guidelines) (yes/no), and societal costs. Mixed model analysis will be performed to compare (the course) of outcomes
between groups. The economic evaluation will be performed from a societal perspective. The implementation process
is investigated using the Tailored Implementation for Chronic Diseases (TICD) framework.
Discussion: Results will add to current knowledge of the (cost-)effectiveness of nurse-led primary healthcare to
improve guideline-concordant care for older women with urinary incontinence. In addition, the results will provide
more insight into care needs and health service utilization of this group of women, as well as into use of absorbent
products in accordance with the recommended criteria in guidelines. Finally, results will increase our understanding
of the intervention’s uptake and could provide useful insights for future dissemination and sustenance.
Trial registration: Dutch Trial Register NTR4396, registered 13-January-2014
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Background
Urinary incontinence (UI) has been defined as the com-
plaint of any involuntary leakage of urine [1]. In
community-dwelling older women, the prevalence of UI
is high and increases with age (from 28% in women be-
tween 55 and 59 years old to 40% in women over 80), as
does severity [2, 3]. The most prevalent UI types in
women aged 55 years and older are stress UI, urgency
UI and mixed UI. Stress UI occurs during activities that
cause a sudden rise in abdominal pressure, such as
coughing or sneezing, while urgency UI manifests as an
irresistible desire to void, followed almost immediately
by loss of urine. Stress UI and urgency UI are estimated
to affect 39 and 15% of older women with UI, respect-
ively. Mixed UI consists of symptoms of both urgency
and stress, and may affect up to 43% of older women
with UI [3]. UI negatively impacts quality of life and role
functioning (e.g., work productivity) [4, 5]. People who
suffer from UI are more likely to experience adverse
health outcomes, such as functional decline and depres-
sion, and are more likely to avoid social activities [6, 7].
Evidence based guidelines recommend that treatment
is tailored to UI type [8–10]. Treatment has shown to be
effective in terms of positively impacting older women’s
UI severity, quality of life, and social participation [11–21].
Depressive feelings due to UI’s impact on daily life may
improve as well by treatment [22]. In addition, evidence
based guidelines recommend that absorbent products are
only used as a coping strategy pending definitive treat-
ment, as an adjunct to ongoing therapy, or for long-term
management after all treatment options have been ex-
plored [8–10]. However, in daily practice these criteria for
long-term use of absorbent products are rarely met in
female users of 55 years and older in The Netherlands
[23–25]. General practitioners (GPs) may not always offer
guideline-concordant care to these women, due to, for in-
stance, the unfounded belief that this type of care is likely
to be ineffective in this age group [23–25].
Better implementation of the UI guidelines could re-
sult in both health benefits for women and long-term
cost savings for society, as absorbent products are a
main long-term cost driver in continence care [26]: in
2014, 487.800 Dutch users of absorbent products re-
ceived reimbursement of these products, with each user
spending on average € 305 a year, resulting in total costs
of almost € 149 million. Better implementation of the
guidelines may be facilitated by nurse supplementation
in community continence care. Nurse supplementation
is defined as adding a nurse to a (primary) care team,
who provide services that supplement the care provided
by physicians and other relevant health professionals
[27]. The aim is to improve quality of care [27]. Evidence
suggests that nurse supplementation can produce better
health outcomes for patients under the conditions that
treatments delivered by nurses are effective and nurses
contribute to the improved delivery of those treatments
[27]. Nurse supplementation may also positively impact
direct healthcare costs, depending on the context in
which the care is provided [27].
However, little is known about the effectiveness of
nurse supplementation in community continence care.
Previous studies that compared nurse supplementation
with usual care or no treatment found small to moderate
short-term effects, but no long-term effects [28–31].
The evidence on cost-effectiveness is even more limited
[28, 30]. A 12-month societal cost-effectiveness analysis
suggested that involvement of a nurse specialist was
more effective and more expensive than usual care pro-
vided by GPs [28]. Furthermore, a decision analytic
model suggested that nurse involvement in general prac-
tice is likely to reduce incontinence, improve quality of
life, and reduce costs [32]. Also, it is unclear in which
setting nurse supplementation to community continence
care is most appropriate. Past efforts to improve con-
tinence care were primarily directed at general practice
[28, 29, 32–35], but did not succeed in improving contin-
ence care. In The Netherlands, community pharmacies
seem an appropriate site to promote guideline-concordant
continence care among women who use absorbent
products, as absorbent products are distributed to users
through pharmacy services and on-site interaction with
patients is frequent. In addition, community pharmacies
may enable nurses to have clear lines of communication
with general practices.
Therefore, this study aims to promote guideline-
concordant continence care for women aged 55 years
and over using absorbent products by means of nurse
supplementation from community pharmacies. The aim
of the guideline-COncordant CONtinence care (COCON)
study is to evaluate the (cost-)effectiveness of a nurse-led
intervention to optimise implementation of guideline-
concordant continence care in comparison with usual care
for urinary incontinent women aged 55 years and over
who use absorbent products. This paper describes the
COCON study protocol.
Methods
Design
We carry out a randomised clinical trial (RCT) to com-
pare the costs and effects of usual care with guideline-
concordant continence care provided by a continence
nurse. The trial will run over a 12-month period among
women of 55 years and older who suffer from UI and
use absorbent products supplied by 12 participating
community pharmacies in three Dutch regions (West-
Friesland, Katwijk and Amsterdam). We will perform an
effect evaluation, an economic evaluation and a process
evaluation. Figure 1 shows the design of the study. The
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COCON study was approved by the medical ethics com-
mittee of the VU University Medical Center (approval
number 2013.389).
Study population
The study population consists of community-dwelling
and urinary incontinent women aged 55 years and over.
All women are long-term users (≥ four months) of
absorbent products prescribed by a medical doctor and
supplied by a community pharmacy. In addition, all
women have sufficient command of the Dutch language
to participate in the trial.
Participant recruitment
Study participants are recruited by means of the follow-
ing process.
(1)Using the inclusion criteria described above,
participating community pharmacies (n = 12)
provide a list of eligible women. Subsequently,
pharmacists exclude women they consider not
eligible to participate (due to dementia or cognitive
impairment; critical or terminal illness/condition;
upcoming transferral to another community
pharmacist).
(2)By mail, women considered eligible for trial entry
receive an invitation to participate in the study.
Within two weeks after receiving the invitation,
women receive a telephone call from a research
assistant who provides further information and asks
women whether they are interested to participate.
Finally, participants provide written informed consent
and complete the baseline assessment.
Randomisation
After obtaining baseline measurements, participants are
randomised using an allocation sequence generated by a
Random Allocation Software program. The allocation
sequence is embedded within the logistic support system
built for the COCON study. After baseline measure-
ments, the system issues the group allocation. Strati-
fied block randomisation per community pharmacy is
used to ensure an even number of participants in each
of the two groups exposed to the same community
pharmacist’s policy.
Fig. 1 Design of the COCON study
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Control group: usual care
Involvement of continence nurses to stimulate guideline
concordant care in women who use absorbent products
is not part of usual care in The Netherlands. Usual care
for UI is based on guidelines [8, 36]. However, GPs’ ad-
herence to guidelines is generally low [25]. Absorbent
product supply and user advice are provided by com-
munity pharmacies. Women need to consult their GP
before gaining access to continence services (an excep-
tion is physiotherapy, which can be accessed without
referral) [8]. Monitoring of a woman’s continence status
after prescribing absorbent products should be done by
the GP [36], but this is rare. The costs of prescription
absorbent products are (partly) reimbursed by health
insurance companies. The majority of companies base
its reimbursement for absorbent products on a fixed
day rate that corresponds to clinical user profiles.
Intervention group: guideline-concordant continence care
provided by a continence nurse
During a one year period, participants receive consulta-
tions with a continence nurse (on average two hours per
year). Based on the Dutch multidisciplinary guideline on
UI in women [8], which is in line with international UI
guidelines such as the NICE guideline [10], the nurse
evaluates and monitors women’s situation and provides
advices on treatment and referrals. The nurse advises,
whereas the GP decides the (strategy for) UI initial or
specialized medical treatment.
To facilitate standardised care delivery, the guideline
was translated into a protocol by two experienced con-
tinence nurses and a nursing researcher. In the protocol,
each health professional’s set of tasks and responsibilities
is delineated: responsibility for a patient’s medical treat-
ment rests with the GP, while responsibility for medica-
tion safety and absorbent products-related advice rests
with the pharmacist. The nurse’s task is to advice a
woman about appropriate continence care (including GP
diagnostics) tailored to the woman’s specific situation, to
support the woman in achieving care agreed on, to evalu-
ate the effects of care, and to monitor continence status.
Based on the protocol, an electronic health record system
was developed with the aim to compel and monitor com-
pliance with the protocol.
The initial consultation, which takes place at a woman’s
community pharmacy or at a women’s location of choice,
involves assessment and investigation of (factors related
to) continence status to tailor recommendations for treat-
ment (including GP diagnostics) to a woman’s needs and
situation (for details, see Additional file 1: Figure S1).
Finally, the nurse supports the woman in decision-making
on an action plan. Subsequent consultations focus on
monitoring continence status and the effects of the ac-
tion plan agreed on, treatment support, co-ordination
of UI care, and evaluation and readjustment of the care
agreed on.
There is a minimum of three (at 3, 6, and 12 months
of follow-up) and a maximum of six contacts by means
of telephone or face-to-face appointments, depending on
the woman’s status (see Additional file 1: Figure S1). All
consults entail information, education and advice about
UI and treatment options. Initially, lifestyle changes and
conservative treatment are indicated (e.g., bladder train-
ing, pelvic floor muscle training). If these do not work,
more invasive treatments can be offered (e.g., surgery).
In case of mixed UI, care is directed towards the pre-
dominant symptoms (stress or urgency). Bladder diaries
are used as an aid in the diagnosis and for the evaluation
of treatment [8]. After each consultation, the nurse re-
ports her findings and recommendations, with the
woman’s consent, to the woman’s GP. The nurse advises
on treatment and care, whereas the GP decides the
(strategy for) UI initial or specialized medical treatment.
Moreover, the nurse informs the pharmacist about the
advice given on absorbent products use.
Evaluation
Measurements are based on the rationale: guideline-
concordant continence care provided by a continence
nurse will lead to increased uptake of guideline-concordant
care by women. This improved uptake will lead to short-
term health benefits in terms of severity of UI, quality of
life, and subsequently depressive symptoms. Based on pre-
vious studies [28–31], we expect that the maximum benefit
will be reached within the first 6 months. In the long term
it is expected that the intervention will lead to cost savings
due to a decrease in the long-term use of absorbent prod-
ucts. Table 1 provides an overview of all measurements for
the effect and economic evaluation.
We perform a process evaluation alongside the trial,
collecting qualitative and quantitative data that will
assist in explaining and interpreting the findings on
(cost-)effectiveness of the intervention. The process
evaluation, guided by principles of the Tailored Imple-
mentation for Chronic Diseases (TICD) framework [37],
will provide insight into the implementation of the inter-
vention. Executed work (Table 2) and user experiences
(Table 3) are the main outcomes of interest. Nurses are
interviewed at the middle and at the end of the project.
Pharmacists and general practitioners are interviewed
mid and post project.. In addition, patient satisfaction is
measured by means of a post-consultation evaluation
questionnaire and an item in the questionnaire at 3, 6,
and 12 months of follow-up.
Effect evaluation
Primary patient outcome is severity of urinary incontin-
ence as measured with the International Consultation on
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Incontinence Questionnaire Short Form (ICIQ-UI SF)
[38]. The questionnaire has shown good validity, reli-
ability, and responsiveness to change [38].
Secondary patient outcomes are:
(1)Health-related quality of life as measured with
the five-level version of the EuroQoL (EQ-5D-5L)
[39, 40];
(2)Urogenital distress as measured with the 6-item
Urogenital Distress Inventory (UDI-6) [41];
(3)Improvement of UI (in the past period) as measured
with the Patient Global Impression of improvement
questionnaire (PGI-I) [42];
(4)Depressive symptoms as measured with the
Center for Epidemiologic Studies Depression
Scale (CES-D) [43].
(5)Use of absorbent products (yes/no) and use of
absorbent products in accordance with the
recommended criteria in guidelines (yes/no) which
is estimated by questions on whether absorbent
products are used as a coping strategy pending
definitive treatment, as an adjunct to ongoing
therapy, or for long-term management after all
treatment options have been explored.
Baseline measures
The following patient characteristics are assessed at
baseline: age, length and weight (Body Mass Index),
parity (number) and type of delivery, UI type, mobility,
flatulence and faecal incontinence (yes/no), comorbidity,
and treatment history.
Sample size calculations
Calculations are based on the expected effects of the inter-
vention on the severity of UI (ICIQ-UI SF), using an equa-
tion for a longitudinal design [44]. Assumptions in the
calculation were: standard deviation 4.0 [29, 45]; correlation
coefficient of repeated measurements 0.6, alpha 0.05; power
95%. To detect a clinically relevant difference of 2 points
[45] on the ICIQ-UI SF between the two groups, the num-
ber of women needed to include is 64 per arm. Anticipating
an attrition rate of 20%, 160 women had to be included.
Analysis
To compare the (course of) outcomes between the two
groups, mixed model analysis will be performed based on
the intention-to-treat principle. First, the characteristics at
baseline will be described and the comparability of the
groups at baseline will be checked using chi-square tests
Table 2 Work executed
Work to be executed: Intervention components Concepts Research questions
- preparation: handed over a bladder diary to fill in during
three days; asked to take morning urine to the consult
- first consultation(s): inventory of questions and needs;
urine test; bladder diary check; history taking; advice,
education and information on UI and appropriate care
options followed by shared decision making on care; referral;
- follow-up consults at 3 and 6 months and at the end of the
project, additional consults aligned with the type of UI and
care agreed on (according to the protocol) to monitor and
evaluate continence status and treatment effects.
- letter to GP and physiotherapist with advices
Nurses’ delivery of activities, type of activities
sequence of activities; collaboration with
community pharmacists, GPs and other
primary continence care professionals
• What proportion of people received
the subsequent intervention
components?
• How often were the intervention
components delivered?
• How were the intervention
components delivered?
Nurses’ protocol adherence and
deviations; decision making on
appropriate treatment advice
• What protocol deviations were
necessary?
• How was decision making reached?
• What changes were proposed and
accepted in care for participating
women?
Table 1 Outcomes and measurements of the effect and economic evaluation
Type of outcome Study entry Baseline 3 months 6 months 12 months
Patient characteristics Checking inclusion & exclusion criteria x
Severity of urinary incontinence (ICIQ-UI SF) x x x x
Health-related quality of life (EQ-5D-5 L) x x x x
Urogenital distress (UDI-6) x x x x
Improvement of UI (PGI-I) x x x
Depressive symptoms (CES-D) x x x x
use of absorbent products (in accordance
with the recommended criteria in guidelines) (yes/no)
x x x x
Costs (retrospective)
questions based on TICP (past period) x x x
pharmacist data (past 12 months) x
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and student’s t-tests or non-parametric tests. Moreover,
potential bias due to differential loss to follow-up will be
checked by comparing the baseline characteristics of those
with and without loss to the follow-up.
Blinding
Due to the nature of the intervention it is not possible to
blind participants and nurses. However, data-analysts will
be blinded during the analytical process. Pharmacists are
blinded to their clients’ allocation status until it is revealed
by the nurse or participants themselves. The research
assistant and the interviewers cannot remain blinded (for
instance, questionnaires in the intervention group contain
questions about satisfaction with the intervention).
Economic evaluation
The economic evaluation will be performed from a so-
cietal perspective. Societal costs will be measured
retrospectively using questions based on the TICP [46]
(see Table 1). Healthcare costs include the costs of GP
care, visits to other primary care providers, ambulatory
and inpatient hospital care, medication, absorbent
products (prescribed products and over-the-counter
products), complementary care, and home care. Patient
costs will include informal care costs. Lost productivity
costs include absenteeism from paid and unpaid work,
and presenteeism. Use of absorbent products will be
retrieved from the pharmacy’s registration system at
the end of the project.
Table 3 User experiences
Factors Concepts Health professionals’ experiences, barriers and
facilitators & possible improvements with regard to:
Guideline related factors Feasibility of the recommended guideline and the
protocol derived from the guideline
- Guideline
- Protocol
- EHR
- Consults
- Collaboration with other continence professionals:
Informing the woman’s GP after the consult by means of
a letter, Advices for referrals, diagnostics and treatments
Compatibility of the protocol: the extent to
which the recommended protocol is practical
likewise
Individual health
professional factors
Competences (=skills, attitude and knowledge)
needed: the extent to which the targeted health
professionals have competences they need
- Competences needed
- Training/educational needs
- Learning experiences
Health professionals’ engagements and satisfaction
with the intervention
- Involvement & Satisfaction (both rated on a 0–10 scale)
Patient factors Patient behaviour: patient’s response to consults - Patient’s response to consults, advices
- Factors that influence patient’s response to nurses’ care,
e.g., financial issues
Patient motivation: the targeted healthcare professional’s
(perceived) ability to motivate patients to adhere
- Motivating patients to adhere
Patient preferences: the targeted healthcare professional’s
(perceived) ability to pay attention to patient preferences
- Paying attention to patient preferences
Professional
interactions
Referral processes: processes for communication between
the targeted healthcare professionals and targeted patients
- Nurse’s interaction with GPs
- Nurse’s interaction with community pharmacists
- Nurse’s interaction between GPs and community pharmacists
Incentives and
resources
Financial incentives: the extent to which patients, individual
health professionals and organisations have financial
incentives or disincentives to adhere
- Financial issues that influenced adherence among patients,
GPs and community pharmacists
Information system: the extent to which the EHR facilitates
or hinders adherence
- EHR
Capacity for
organisational change
Mandate, authority and accountability for making
necessary changes
- Mandate for treatment change in participating women.
Regulations, rules, policies: the extent to which
organisational regulations, rules or policies facilitate or
hinder necessary changes.
- Regulations, rules and policies.
Social, political and
legal factors
Payer or funder policies: the extent to which payer or funder
policies may affect implementation of necessary changes
- Payer or funder policies facilitating or hindering
implementation of necessary changes
Legislation: the extent to which legislation may affect
implementation of necessary changes
- Legislation affecting implementation of necessary changes
EHR Electronic Health Record, GP General Practitioner
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The friction cost approach will be used to estimate lost
productivity costs [47]. For the valuation of health care
utilisation, standard prices published in the Dutch cost-
ing guidelines will be used [48]. Medication costs will be
valued using prices of the Royal Dutch Society for Phar-
macy [49]. Costs of the intervention will be estimated
using a bottom-up approach.
The analysis will be performed according to the
intention-to-treat principle. Missing cost and effect data
will be imputed using multiple imputation according to
the MICE algorithm developed by Van Buuren [50]. In-
cremental cost-effectiveness ratios (ICERs) will be calcu-
lated by dividing the difference in the mean total costs
between the two groups by the difference in mean ef-
fects between the two groups in (1) severity of UI as
measured by the ICIQ-UI SF and (2) quality-adjusted
life-years (QALYs) based on the Dutch tariff for the five-
level version of the EuroQol questionnaire [39, 51]. Bi-
variate regression models will be used to estimate cost
and effect differences while adjusting for confounding if
necessary. Statistical uncertainty will be estimated using
bias-corrected accelerated bootstrapping with 5000 rep-
lications. Uncertainty surrounding the ICERs will be pre-
sented in cost-effectiveness planes and acceptability
curves [52, 53]. The policy cost-effectiveness of the
intervention will also be estimated using the model de-
veloped by Mason et al. [54].
Reach of the study
We will explore the reach of the study to gain insight into
participants’ representativeness of the target population
and associated generalizibility of the results. After recruit-
ment, we collect data among non-participants on the
underlying reasons for not participating in the study, and
UI-related characteristics (including the primary outcome)
by means of a questionnaire. These UI-related data of re-
fusers will be compared with data of participants.
Discussion
The aim of the COCON study is to evaluate the (cost-)
effectiveness of a nurse-led intervention to optimise im-
plementation of guideline-concordant continence care in
comparison with usual care for urinary incontinent women
aged 55 years and over who use absorbent products.
Results will add to current knowledge of the cost-
effectiveness of nurse-led primary healthcare to im-
prove guideline-concordant care for women with UI. In
addition, the results will provide more insight into care
needs and health service utilization of this group of
women, as well as into use of absorbent material in ac-
cordance with the recommended criteria in guidelines.
Finally, results will increase our understanding of the
strategy’s uptake and could provide useful insights for
future dissemination and sustenance.
The COCON study differs from previous studies that
aimed to improve guideline implementation among
women with urinary incontinence in several aspects. First,
this study targets only older women with urinary incontin-
ence who are long term users of absorbent products,
whereas previous studies focused on all (older) women
with urinary incontinence [28, 31, 34]. A second difference
is that this study does not rely on GPs [28, 29, 32–35] but
is initiated from community pharmacies where women
pick up their absorbent products. Third, this study uses a
web-based protocol aimed at optimising uniformity of
care delivery and facilitating the monitoring of this de-
livery. Last, this is one of the first studies to investigate
cost-effectiveness of guideline-concordant continence
care provided by a continence nurse [28, 30].
Strengths of this study include alignment of measure-
ments with the rationale; the absence of potential con-
tamination of the usual care group as this group has no
access to the intervention; a process evaluation alongside
the trial that will support the interpretation of findings
on (cost)effectiveness of the intervention, inclusion of
data from women’s consultations with the continence
nurse; and insight into (potentially selective) drop-out
and refusal of women to enable understanding of the
representativeness of participating women and the asso-
ciated generalisibility of study results.
There are also some limitations of the study. First, select-
ive participation of women is plausible as not all women
will accept the consultations with a continence nurse.
However, in this study data are collected to gain insight in
(potentially selective) drop-out and refusal of women. This
will also help to determine which women can be success-
fully reached by means of this type of strategy in the future.
Second, the use of retrospective self-reports on health
service utilization might be less valid compared with
administrative data. However, as administrative data is
not available (with the exception of absorbent products
use), self-reports are a good alternative [55].
Despite these limitations, study results will increase our
understanding of the uptake and (cost-) effectiveness of
nurse supplementation in community continence care.
Moreover, we expect that better implementation of the UI
guidelines in older women using absorbent products dur-
ing four months or more can result in both health benefits
for women and long-term cost savings for society.
Trial status
The study commenced recruitment in August 2014 and
has completed enrolment of participants in March 2015.
The study is currently completing follow-up procedures
concerning pharmacist record abstraction. Data cleaning
and analysis have not begun. We anticipate that results
will be available in March 2017. Some elements of the
current study protocol depart from the registered
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protocol in the Dutch Trial Register (NTR4396): First,
we planned a cluster RCT (to overcome potential con-
tamination) and changed this into a randomisation at a
patient level as we noticed that there was no risk of con-
tamination at all, and less participants were necessary
(160 instead of 252) to execute our study with the same
power. Second, initially, we planned to have no exclusion
criteria and changed this at request of participating com-
munity pharmacists in order to align our study with daily
practice. Last, we planned a multifaceted intervention
entailing the current intervention and financial incentives
for pharmacies contributing to guideline concordant care.
We dropped the financial incentives as only the nurse and
GP can have impact on uptake of guideline concordant
care, not the pharmacists.
Additional file
Additional file 1: Figure S1. Flow chart nurse’s intervention. (PDF 92 kb)
Abbreviations
EHR: Electronic health record; GP: General practitioner; UI: Urinary incontinence
Acknowledgements
We would like to acknowledge all participating community pharmacies, GPs,
nurses (Monique Janssen-Krieger and Marja Kluyver), and participants. We
are grateful to Farmaceutisch Bureau Amsterdam for collaborating with us.
Funding
The COCON-study is funded by The Netherlands Organization for Health
Research and Development (ZonMw): Health efficiency Program, grant
number 837003004. The involvement of nurses has been funded by Fonds
NutsOhra, grant number 1305–231. The funders had no role in study design
and in writing the manuscript. They (will) have no role in data collection,
analysis and preparation of future manuscripts.
Availability of data and materials
The VU University Medical Center acknowledges the interest of sharing
datasets after the primary authors have published all their manuscripts based
on these data. After all data have been analyzed and the results have been
published the Department’s Board agrees to share anonymous data.
Authors’ contributions
AJ (principal investigator) and HV led the application for funding. They
designed the study protocol in close collaboration with JB, ML, PV, BB,
GN, JD, JH and MM. JB designed the economic evaluation; ML and MM
contributed to the design of the process evaluation and fundaments of
the implementation strategy; PH and BB contributed especially to the UI-
related parts of the protocol. AJ and MM wrote this protocol manuscript.
All authors provided critical commentary to the manuscript and agreed
with this final version.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The COCON study was approved by the medical ethics committee of the VU
University Medical Center (approval number 2013.389). Participating women
are requested to sign their informed consent.
Author details
1Amsterdam Public Health research institute, VU University Medical Center,
Amsterdam, The Netherlands. 2Department of General Practice and Elderly
Care Medicine, VU University Medical Center, Amsterdam, The Netherlands.
3Department of Health Sciences and Amsterdam Public Health research
institute, Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, The
Netherlands. 4Maastricht University, Maastricht, The Netherlands; Pelvic care
Center Maastricht, Maastricht University Medical Centre, Maastricht, The
Netherlands. 5Department of General Practice, University of Groningen;
University Medical Center Groningen, Groningen, The Netherlands.
6Department of Clinical Pharmacology and Pharmacy, VU University Medical
Center, Amsterdam, The Netherlands. 7Zonnehuisgroep Amstelland,
Amstelveen, The Netherlands. 8Faculty of Health and Social Studies, HAN
University of Applied Sciences, Nijmegen, The Netherlands. 9Radboud
University Medical Center, Radboud Institute for Health Science, IQ
healthcare, Nijmegen, The Netherlands. 10Department of Obstetrics and
Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Received: 30 July 2016 Accepted: 9 February 2017
References
1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An
International Urogynecological Association (IUGA)/International Continence
Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
Neurourol Urodyn. 2010;29:4–20.
2. Ebbesen MH, Hunskaar S, Rortveit G, Hannestad YS. Prevalence, incidence
and remission of urinary incontinence in women: longitudinal data from
the Norwegian HUNT study (EPINCONT). BMC Urol. 2013;13:27.
3. Hannestad YS, Rortveit G, Hunskaar S. Help-seeking and associated
factors in female urinary incontinence. The Norwegian EPINCONT Study.
Epidemiology of Incontinence in the County of Nord-Trondelag. Scand J
Prim Health Care. 2002;20:102–7.
4. Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on
quality of life of the elderly. Am J Manag Care. 2005;11:S103–11.
5. Monz B, Pons ME, Hampel C, Hunskaar S, Quail D, Samsioe G, et al. Patient-
reported impact of urinary incontinence–results from treatment seeking
women in 14 European countries. Maturitas. 2005;52 Suppl 2:24–34.
6. Dugan E, Cohen SJ, Bland DR, Preisser JS, Davis CC, Suggs PK, et al. The
association of depressive symptoms and urinary incontinence among
older adults. J Am Geriatr Soc. 2000;48:413–6.
7. Farage MA, Miller KW, Berardesca E, Maibach HI. Psychosocial and societal
burden of incontinence in the aged population: a review. Arch Gynecol
Obstet. 2008;277:285–90.
8. KKCZ/ZonMw (The Netherlands Organisation for Health Research and
Development). Dutch multidisciplinary guideline on urinary incontinence
in women. Utrecht: Programma Kennisbeleid Kwaliteit, The Netherlands
Organisation for Health Research and Development; 2011.
9. NICE. Urinary incontinence: the management of urinary incontinence in
women (CG40). NICE; 2006. https://www.nice.org.uk/guidance/cg40.
10. NICE. Urinary incontinence in women: management (CG171). NICE; 2013.
https://www.nice.org.uk/guidance/cg171.
11. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Nijholt AA, Siegel S,
Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding
dysfunction: outcomes of a prospective, worldwide clinical study. J Urol.
2007;178:2029–34.
12. Lapitan MC, Cody JD. Open retropubic colposuspension for urinary
incontinence in women. Cochrane Database Syst Rev. 2012;6:CD002912.
13. Ward K, Hilton P. Prospective multicentre randomised trial of tension-free
vaginal tape and colposuspension as primary treatment for stress
incontinence. BMJ. 2002;325:67.
14. Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized,
controlled trials of nonsurgical treatments for urinary incontinence in
women. Ann Intern Med. 2008;148:459–73.
15. Teunissen TA, de Jonge A, Lagro-Janssen AL. Treating urinary incontinence
in the elderly–conservative therapies that work: a systematic review.
J Fam Pract. 2004;53:25–32.
16. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary
incontinence in adults. Cochrane Database Syst Rev. 2004:CD001308. doi:10.
1002/14651858.CD001308.pub2.
Jansen et al. BMC Nursing  (2017) 16:10 Page 8 of 9
17. Dumoulin C, Hay-Smith EJ, Mac Habee-Seguin G. Pelvic floor muscle
training versus no treatment, or inactive control treatments, for urinary
incontinence in women. Cochrane Database Syst Rev. 2014;5:CD005654.
18. Hay Smith J, Berghmans B, Burgio K, Dumoulin C, Hagen S, Moore K, et al.
Adult conservative management. In: Abrahams P, Cardozo L, Khoury S,
Wein A, editors. Incontinence. Paris: 4th International Consultation on
Incontinence; 2009. p. 1025–120.
19. Chang J, Dmochowski R, Hilton P, Nilsson CG, Reid FM, Rovner E. Surgery
for urinary incontinence. In: Abrahams P, Cardozo L, Khoury S, Wein A,
editors. Incontinence. Paris: 4th International Consultation on Incontinence;
2009. p. 1192–272.
20. Moore K, Dumoulin C, Bradley C, Burgio K, Chambers T, Hagen S, et al. Adult
conservative management. In: Abrahams P, Cardozo L, Khoury S, Wein A,
editors. Incontinence. Paris: 5th International Consultation on Incontinence;
2013. p. 1101–228.
21. Roger P, Dmochowski R, Athanasiou S, Reid FM, Kraus S, Nitti V, et al.
Surgery for urinary incontinence. In: Abrahams P, Cardozo L, Khoury S,
Wein A, editors. Incontinence. Paris: 5th International Consultation on
Incontinence; 2013. p. 1307–76.
22. Kafri R, Kodesh A, Shames J, Golomb J, Melzer I. Depressive symptoms and
treatment of women with urgency urinary incontinence. Int Urogynecol J.
2013;24:1953–9.
23. Penning-van Beest FJ, Sturkenboom MC, Bemelmans BL, Herings RM.
Undertreatment of urinary incontinence in general practice. Ann
Pharmacother. 2005;39:17–21.
24. van Gerwen MA, Schellevis FG, Lagro-Janssen AL. Management of urinary
incontinence in general practice: data from the Second Dutch National
Survey. J Eval Clin Pract. 2009;15:341–5.
25. Albers-Heitner P, Berghmans B, Nieman F, Lagro-Janssen T, Winkens R.
Adherence to professional guidelines for patients with urinary incontinence by
general practitioners: a cross-sectional study. J Eval Clin Pract. 2008;14:807–11.
26. www.gipdatabank.nl. 2014. (online source entailing Dutch figures on
health utilization).
27. Laurant MGH. The effectiveness of nurse supplementation in primacy care: a
systematic review and meta-analysis. In: Changes in skill mix. The impact of
adding nurses to the primary care team. Nijmegen: Radboud University
Nijmegen; 2007.
28. Albers-Heitner CP, Joore MA, Winkens RA, Lagro-Janssen AL, Severens JL,
Berghmans LC. Cost-effectiveness of involving nurse specialists for adult
patients with urinary incontinence in primary care compared to care-as-
usual: an economic evaluation alongside a pragmatic randomized controlled
trial. Neurourol Urodyn. 2012;31:526–34.
29. Albers-Heitner PC, Lagro-Janssen TA, Joore MM, Berghmans BL, Nieman FF,
Venema PP, et al. Effectiveness of involving a nurse specialist for patients
with urinary incontinence in primary care: results of a pragmatic multicentre
randomised controlled trial. Int J Clin Pract. 2011;65:705–12.
30. Du Moulin MF, Hamers JP, Paulus A, Berendsen C, Halfens R. The role of the
nurse in community continence care: a systematic review. Int J Nurs Stud.
2005;42:479–92.
31. Du Moulin MF, Hamers JP, Paulus A, Berendsen CL, Halfens R. Effects of
introducing a specialized nurse in the care of community-dwelling women
suffering from urinary incontinence: a randomized controlled trial. J Wound
Ostomy Continence Nurs. 2007;34:631–40.
32. Holtzer-Goor KM, Gaultney JG, van Houten P, Wagg AS, Huygens SA, Nielen MM,
et al. Cost-effectiveness of including a nurse specialist in the treatment of urinary
incontinence in primary care in the Netherlands. PLoS One. 2015;10:e0138225.
33. Visser E, de Bock GH, Messelink EJ, Schram AJ, Kollen BJ, la Bastide-van GS,
et al. Active encouragement of older women with urinary incontinence in
primary care to undergo diagnosis and treatment: a matched-pair cluster
randomized controlled trial. Maturitas. 2015;80:212–9.
34. Visser E. Offering care to older community-dwelling women with urinary
incontinence. Groningen: University of Groningen; 2014.
35. Teunissen DT, Stegeman MM, Bor HH, Lagro-Janssen TA. Treatment by a
nurse practitioner in primary care improves the severity and impact of urinary
incontinence in women. An observational study. BMC Urol. 2015;15:51.
36. Dutch College of General Practitioners, wokgroup urinary incontinence in
women. Guideline urinary incontinence in women. 2015.
37. Jager C, Freund T, Steinhauser J, Aakhus E, Flottorp S, Godycki-Cwirko M,
et al. Tailored Implementation for Chronic Diseases (TICD): a protocol for
process evaluation in cluster randomized controlled trials in five European
countries. Trials. 2014;15:87.
38. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief
and robust measure for evaluating the symptoms and impact of urinary
incontinence. Neurourol Urodyn. 2004;23:322–30.
39. Versteegh M, Vermeulen M, Evers AA, de Wit GA, Prenger R, Stolk A. Dutch
tariff for the five-level version of EQ-5D. Value Health. 2016;19:343–52.
40. EuroQol Group. EuroQol–a new facility for the measurement of health-
related quality of life. Health Policy 1990;16:199–208.
41. Svatek R, Roche V, Thornberg J, Zimmern P. Normative values for the
American Urological Association Symptom Index (AUA-7) and short form
Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting
for non-urological care. Neurourol Urodyn. 2005;24:606–10.
42. Yalcin I, Bump RC. Validation of two global impression questionnaires for
incontinence. Am J Obstet Gynecol. 2003;189:98–101.
43. Radloff LS. The CES-D scale: a self-report depression scale for research in
the general population. Appl Psychol Meas. 1977;1:385–401.
44. Twisk JWR. Applied longitudinal data analysis for epidemiology: a practical
guide. Cambridge: Cambridge University Press; 2003.
45. Sherburn M, Bird M, Carey M, Bo K, Galea MP. Incontinence improves in older
women after intensive pelvic floor muscle training: an assessor-blinded
randomized controlled trial. Neurourol Urodyn. 2011;30:317–24.
46. Hakkaart-van Roijen L. Handleiding TiC-P vragenlijst voor zorggebruik en
productieverliezen bij psychische aandoeningen. Rotterdam, iMTA, Erasmus
Universiteit Rotterdam. 2002.
47. Koopmanschap MA, Rutten F. A practical guide for calculating indirect
costs of disease. Pharmacoeconomics. 1996;10(5):460–6.
48. Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanters T, Tan SS.
Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen
voor economische evaluaties in de gezondheidszorg. Rotterdam: Institute
for Medical Technology Assessment; 2016.
49. Z-index. G-standaard. 2016. https://www.z-index.nl/g-standaard.
50. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood
pressure covariates in survival analysis. Stat Med. 1999;18:681–94.
51. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development
and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L).
Qual Life Res. 2011;20:1727–36.
52. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves–facts,
fallacies and frequently asked questions. Health Econ. 2004;13:405–15.
53. Stinnett AA, Mullahy J. Net health benefits: a new framework for the
analysis of uncertainty in cost-effectiveness analysis. Med Decis Making.
1998;18:S68–80.
54. Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M.
When is it cost-effective to change the behavior of health professionals?
JAMA. 2001;286:2988–92.
55. Longobardi T, Walker JR, Graff LA, Bernstein CN. Health service utilization in
IBD: comparison of self-report and administrative data. BMC Health Serv Res.
2011;11:13.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jansen et al. BMC Nursing  (2017) 16:10 Page 9 of 9
